Releases a slow moving mistTiotropium bromide (brand name: Spiriva) has been available as a once daily dry powder bronchodilator for over 10 years. On September 25, 2014, the United States Food and Drug Administration (FDA) approved Spiriva in a new device called the Respimat. It is once daily bronchodilator for treating patients with COPD. When inhaled deep into the lungs, this slow moving mist opens the breathing tubes (airways) to make it easier to breathe. In January 2015, Spiriva Respimat became available in pharmacies in the United State as a prescription medication, while it has been available in Europe for some time. The Respimat is used to deliver two other inhaled bronchodilators – albuterol and ipratropium combination (brand name: Combivent) and olodaterol (brand name: Striverdi). Spiriva inhaled from the HandiHaler and from the Respimat have the same overall effects on opening the airways and making it easier to breathe. The different devices provide choices for patients with COPD. According to Boehringer Ingelheim Pharmaceuticals, Inc., the most common side effects reported with Spiriva Respimat include sore throat, cough, dry mouth, and sinus infection. If Spiriva Respimat is prescribed for you, make sure to review inhaling instructions with your health care provider or pharmacist. The dose is two inhalations once daily. You should inhale slow and steady and then hold your breath as long as possible (up to 10 seconds if you can). This medication should be used with caution if you have narrow-angle glaucoma or difficulty urinating.
You should always discuss any new medication or delivery system with your doctor.